Busch, CatharinaFraser-Bell, SamanthaIglicki, MatiasLupidi, MarcoCouturier, AudeChaikitmongkol, VorapornGiancipoli, ErmeteRodríguez-Valdés, Patricio J.Gabrielle, Pierre-HenriLaíns, InêsSantos, Ana RitaCebeci, ZaferAmphornphruet, AtcharaDegenhardt, ValentinUnterlauft, Jan-DariusCagini, CarloMané-Tauty, ValérieRicci, D'Amico GiuseppeHindi, IsaacAgrawal, KushalChhablani, JayLoewenstein, AnatZur, DinahRegak, Matus2021-02-092021-02-092019-09-21Busch, C., Fraser-Bell, S., Iglicki, M. et al. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol 56, 1341–1350 (2019). https://doi.org/10.1007/s00592-019-01416-4http://hdl.handle.net/10400.22/16930The beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was main- tained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.engRefractory diabetic macular edemaAnti-VEGF therapyDexamethasone implantIntravitreal therapyLong- term outcomejournal article10.1007/s00592-019-01416-4